In Vivo CAR-T Delivery Achieves Tumor Control and Immune Reset in Preclinical Models

Published on Science

Researchers have demonstrated a method for generating CAR T cells inside the body using CD8-targeted lipid nanoparticles loaded with anti-CD19 mRNA. The treatment showed tumor suppression in rodent models and deep, temporary B cell depletion in primates. In autoimmune disease models, this led to a re-emergence of naïve B cells, hinting at a potential immune system reset. This in vivo delivery system eliminates the need for complex cell manufacturing and could expand access to CAR-T therapy.

Read the full article on Science:

👉 In Vivo CAR T Cell Generation to Treat Cancer and Autoimmune Disease

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.